1. Home
  2. WNEB vs OABI Comparison

WNEB vs OABI Comparison

Compare WNEB & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.81

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

HOLD

Current Price

$4.48

Market Cap

294.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
OABI
Founded
1853
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
294.3M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
WNEB
OABI
Price
$13.81
$4.48
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$13.67
$4.50
AVG Volume (30 Days)
49.6K
1.7M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
6.56
EPS
0.42
N/A
Revenue
$44,000.00
$18,666,000.00
Revenue This Year
N/A
$52.42
Revenue Next Year
$7.25
$64.69
P/E Ratio
$32.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.78
$1.32
52 Week High
$15.01
$4.93

Technical Indicators

Market Signals
Indicator
WNEB
OABI
Relative Strength Index (RSI) 47.32 76.67
Support Level $13.28 $1.65
Resistance Level $13.96 N/A
Average True Range (ATR) 0.25 0.31
MACD -0.00 0.08
Stochastic Oscillator 38.85 74.31

Price Performance

Historical Comparison
WNEB
OABI

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: